Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 03, 2015 5:11 AM ET

Healthcare Providers and Services

Company Overview of Enzo Clinical Labs, Inc.

Company Overview

Enzo Clinical Labs, Inc. operates clinical reference laboratories in the United States. It offers various assays in the areas of chemistry, fertility and hormone studies, pregnancy, hematology, and coagulation. The company also provides electronic report delivery services for physicians. In addition, it offers phlebotomy services for patients needing blood tests through its network of patient service centers; diagnostic test that assists in risk assessment and early detection of lung cancer; and ColonSentry, a blood test to assess an individual's current risk for colorectal cancer. Enzo Clinical Labs, Inc. is based in Farmingdale, New York. The company has patient service centers in Manhatta...

60 Executive Boulevard

Farmingdale, NY 11735

United States

Phone:

631-755-5500

Fax:

631-755-5561

Key Executives for Enzo Clinical Labs, Inc.

Chairman of the Board and Chief Executive Officer
Age: 72
President of Enzo Biochem Inc
Age: 65
Medical Director
Scientific Director and Associate Medical Director
Medical Director
Compensation as of Fiscal Year 2015.

Enzo Clinical Labs, Inc. Key Developments

Enzo Clinical Labs Announces Unaudited Earnings Results for the Third Quarter Ended April 30, 2015

Enzo Clinical Labs announced unaudited earnings results for the third quarter ended April 30, 2015. For the quarter, the company revenues grew to $15.7 million, an 8% increase over the prior year period. Operating income was $0.3 million, a $3.6 million turnaround from a year ago.

Enzo Clinical Labs, Inc. Reports Unaudited Earnings Results for the First Quarter Ended October 31, 2014

Enzo Clinical Labs, Inc. reported unaudited earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported that its results benefited from several factors, including greater emphasis and use of molecular diagnostic testing and increased operating efficiencies from streamlining efforts and recently implemented process and operational enhancements. Revenues increased 6%, to a record $15.8 million. Operating income was essentially breakeven, a $900,000 improvement compared to a year ago operating loss of approximately $0.9 million, and EBITDA was a positive $0.4 million, compared to last year’s negative EBITDA of $0.5 million.

Enzo Clinical Labs and Nuclea Biotechnologies Join to Market New Test for Certain High Risk Breast Cancer Patients

Enzo Biochem Inc. announced that its Enzo Clinical Labs subsidiary and Nuclea Biotechnologies, Inc. have entered into a non-exclusive distribution agreement to market Nuclea's non-invasive HER-2/neu serum test, a key assay in the monitoring of metastatic breast cancer. This blood test facilitates the monitoring and treatment decisions of women with metastatic breast cancer that over expresses the HER-2/neu protein in the tumor. Individuals with this condition tend to have a worse prognosis and a more aggressive disease that can resist certain types of chemotherapy. The test measures the portion of HER-2/neu protein that lies outside the surface of the cell and being released into the blood stream, allowing for more informed treatment decisions for a number of women who may not be responding to breast cancer treatment or may be at risk for metastatic cancer and need revised treatment plans. Utilizing the HER-2/neu blood test while monitoring the disease's progression will enable physicians to better adapt, combine therapies and change treatment protocols. Studies have demonstrated that use of combination chemotherapy regimens provides a statistically significant advantage for survival and tumor response in women with metastatic breast cancer.

Similar Private Companies By Industry

Company Name Region
SuperBlue HMO United States
Community Systems United States
Western Washington Endoscopy Centers, LLC United States
Kimathi Pediatric Dentistry, P.C. United States
Future Care Irvington, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Enzo Clinical Labs, Inc., please visit www.enzo.com/clinicallabs/index.asp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.